IGC Pharma, INC. About us
We are a focused Clinical-Stage
Pharmaceutical company.
Our Purpose
Is to improve the health and well-being of women and their families through the discovery and development of innovative therapies for neurological disorders like Alzheimer’s disease, bringing these therapies to market.
Formerly known as India Globalization Capital, Inc., we were incorporated in Maryland on April 25, 2005. Our fiscal year is the 52- or 53-week period ending March 31.
Pioneering Alzheimer's Solutions:
Our Dedication to Progress
TGR-63 is designed to disrupt the progression of Alzheimer’s disease by targeting Aβ plaques. IGC-M3 aims to inhibit Aβ plaque aggregation, potentially making a profound impact on early-stage Alzheimer’s. IGC-1C focuses on tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy.
Committed to scientific excellence and patient-centered innovation, our goal is to advance the understanding and treatment of various brain-related conditions.
We are committed to introducing